On Tuesday, Halozyme Therapeutics Inc (NASDAQ: HALO) opened at On Tuesday, remained unchanged from the last session, before settling in for the closing price of $49.06. Price fluctuations for HALO have ranged from $33.15 to $65.53 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 41.16% over the last five years. Company’s average yearly earnings per share was noted 43.80% at the time writing. With a float of $125.88 million, this company’s outstanding shares have now reached $127.18 million.
The firm has a total of 373 workers. Let’s measure their productivity. In terms of profitability, gross margin is 78.34%, operating margin of 50.35%, and the pretax margin is 50.68%.
Halozyme Therapeutics Inc (HALO) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Halozyme Therapeutics Inc is 1.06%, while institutional ownership is 99.40%. The most recent insider transaction that took place on Oct 15 ’24, was worth 537,469. In this transaction SVP, CHIEF TECHNICAL OFFICER of this company sold 10,000 shares at a rate of $53.75, taking the stock ownership to the 173,756 shares. Before that another transaction happened on Oct 16 ’24, when Company’s SVP, CHIEF TECHNICAL OFFICER sold 10,000 for $53.26, making the entire transaction worth $532,590. This insider now owns 173,756 shares in total.
Halozyme Therapeutics Inc (HALO) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.07 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 43.80% per share during the next fiscal year.
Halozyme Therapeutics Inc (NASDAQ: HALO) Trading Performance Indicators
Check out the current performance indicators for Halozyme Therapeutics Inc (HALO). In the past quarter, the stock posted a quick ratio of 9.15. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.59. Likewise, its price to free cash flow for the trailing twelve months is 15.89.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 3.02, a number that is poised to hit 1.17 in the next quarter and is forecasted to reach 4.60 in one year’s time.
Technical Analysis of Halozyme Therapeutics Inc (HALO)
Analysing the last 5-days average volume posted by the [Halozyme Therapeutics Inc, HALO], we can find that recorded value of 0.94 million was lower than the volume posted last year of 1.36 million. As of the previous 9 days, the stock’s Stochastic %D was 73.35%. Additionally, its Average True Range was 1.97.
During the past 100 days, Halozyme Therapeutics Inc’s (HALO) raw stochastic average was set at 29.97%, which indicates a significant decrease from 84.07% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 32.64% in the past 14 days, which was lower than the 51.62% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $52.28, while its 200-day Moving Average is $49.92. Now, the first resistance to watch is $49.79. This is followed by the second major resistance level at $50.53. The third major resistance level sits at $51.26. If the price goes on to break the first support level at $48.32, it is likely to go to the next support level at $47.59. Should the price break the second support level, the third support level stands at $46.85.
Halozyme Therapeutics Inc (NASDAQ: HALO) Key Stats
There are currently 127,227K shares outstanding in the company with a market cap of 6.24 billion. Presently, the company’s annual sales total 829,250 K according to its annual income of 281,590 K. Last quarter, the company’s sales amounted to 290,080 K and its income totaled 137,010 K.
